Bonabes Olivier De Rouge

Title: Bonabes Olivier De Rouge: Innovator in Scorpion Venom Research

Introduction

Bonabes Olivier De Rouge is a notable inventor based in Paris, France. He has made significant contributions to the field of biochemistry, particularly through his research on peptides derived from scorpion venom. His work focuses on the development of innovative treatments for autoimmune diseases.

Latest Patents

De Rouge holds a patent for OsK1 derivatives. OsK1 is a 38-residue peptide characterized by three disulphide bridges, which is found in the venom of the scorpion. This peptide exhibits potent activity on voltage-gated K channels Kv1.1, Kv1.2, and Kv1.3, while also showing moderate activity on the type 1 intermediate-conductance Ca2+-activated channel K3.1. The derivatives of OsK1, particularly those involving truncation or point mutations, have been developed to enhance their activity against and selectivity for the Kv1.3 channel. This advancement positions these derivatives as promising candidates for the treatment of autoimmune diseases, including multiple sclerosis, either alone or in combination therapy with maurotoxin, another scorpion toxin.

Career Highlights

De Rouge is associated with Cellpep Pharma Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on therapeutic strategies for autoimmune conditions.

Collaborations

He collaborates with esteemed colleagues such as Stephanie Mouhat and Jean-Marc Sabatier, contributing to a dynamic research environment focused on innovative solutions in biochemistry.

Conclusion

Bonabes Olivier De Rouge exemplifies the spirit of innovation in the field of peptide research, particularly through his work with scorpion venom derivatives. His contributions hold promise for the future of treatments for autoimmune diseases.